Three independent discounted-cash-flow-style models value Pacira BioSciences, Inc. Common Stock every trading day. 0 of 3 currently price PCRX above its market price.
| Free Cash Flow model | $10.46 |
| Excess Profit model | $-31.11 |
| Residual Earnings model | $-1.59 |
| Dividend Discount model | — |
| Piotroski F-Score | 8 / 9 |
| Return on invested capital | +1.4% |
| Net debt / EBITDA | 19.4× |
| Gross margin | +79.4% |
| Revenue CAGR | +10.3% |
| Cash conversion | 21.6× |
| Dividend yield | — |
| Buyback yield | +3.6% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open PCRX in StockKitty